01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#VELA Vela Technologies – Investee Company #KING Igraine Plc Notice of AGM and Share Purchase October 13, 2022 – Posted in: Blog, Vela Technologies Plc (VELA)

  SHARE PURCHASE Igraine Plc is pleased to announce that it has [today] purchased 21,475,000 ordinary shares of Oscillate plc, representing approximately 10.2% of Oscillate’s issued share capital, for a total consideration of  £268,437. This diversifies the Igraine holding with the idea of obtaining pre-IPO positions in companies that have sufficient cash resources to undertake transactions. Simultaneously with the share purchase, it has been agreed that Stephen Winfield, Executive Director of the Company, will join…

Continue reading

#POLB Poolbeg Pharma PLC – CEO Share Purchase October 6, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

6 October 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has been notified that Chief Executive Officer, Jeremy Skillington, has purchased 718,733 ordinary shares of 0.02 pence each in the Company (“Ordinary Shares”) at a share price of 4.78 pence per share. Following the purchase, Jeremy Skillington’s beneficial interest in the Company is 718,733 Ordinary Shares, representing…

Continue reading

#ORPH Open Orphan plc – Positive in vitro results for FLU-v published September 30, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that positive data from a peer-reviewed study evaluating the in vitro efficacy of FLU-v, Imutex Limited’s (“Imutex”) broad spectrum influenza vaccine, has been published in the scientific journal Vaccines.1   Previous clinical studies have demonstrated that FLU-v induced increased…

Continue reading

#ORPH Open Orphan – Vaccine field study contract May 5, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO , a subsidiary of Open Orphan, has been awarded a new study with an existing Big Pharma client to act as a vaccination site for a Phase II field study of the client’s respiratory syncytial virus (RSV) vaccine candidate.   As part of the study, hVIVO will…

Continue reading